Physician profile
Tyson Tanner
NPI 1851529598
$3,149.60
in general payments reported to CMS, 2019-2025
22 companies · $504 in 2025
The $504 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $276 · 2021: $304 · 2022: $860 · 2023: $408 · 2024: $378 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.50 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $492.71 | 2022 | |
| Bausch & Lomb Americas INC. | $373.31 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $332.40 | 2019-2023 | |
| Alcon Vision LLC | $331.02 | 2022-2025 | Tryptyr, Rocklatan, Clareon Panoptix Pro |
| Allergan, INC. | $281.93 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $273.50 | 2019-2021 | |
| Abbvie INC. | $171.83 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $158.39 | 2021-2024 | Cequa |
| Harrow Eye, LLC | $148.14 | 2024-2025 | Vevye, Natacyn, Tobradex St |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.91 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $91.81 | 2020-2022 | |
| Amgen INC. | $84.91 | 2024-2025 | Tepezza |
| Dompe US, INC. | $50.41 | 2025 | Oxervate |
| Thea Pharma INC. | $49.38 | 2022-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $37.41 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $35.16 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $30.31 | 2023 | Tepezza |
| Astellas Pharma US INC | $23.12 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $22.66 | 2023 | Tyrvaya |
| Shire North American Group INC | $17.67 | 2019 | |
| Sight Sciences, INC. | $17.15 | 2022 | |
| Vyera Pharmaceuticals, LLC | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyson Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.